Literature DB >> 34072248

State-Level Health Disparity Is Associated with Sarcoidosis Mortality.

Yu-Che Lee1, Ko-Yun Chang2, Mehdi Mirsaeidi3,4.   

Abstract

BACKGROUND: Sarcoidosis is associated with significant morbidity and rising health care utilization, which contribute to the health care burden and disease outcome. In the United States (US), evaluation of sarcoidosis mortality by individual states has not been investigated.
METHODS: We examined sarcoidosis mortality data for 1999-2018 from the Centers for Disease Control and Prevention (CDC). America's Health Rankings (AHR) assesses the nation's health on a state-by-state basis to determine state health rankings. The numbers of certified Sarcoidosis Clinics within the US were obtained from World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG) and Foundation for Sarcoidosis Research (FSR). The associations between sarcoidosis mortality and state health disparities were calculated by linear regression analyses.
RESULTS: From 1999 to 2018, the mean age-adjusted mortality rate (AAMR) in all populations, African Americans and European Americans were 2.9, 14.8, and 1.4 per 1,000,000 population, respectively. South Carolina had the highest AAMR for all populations (6.6/1,000,000) and African Americans (20.8/1,000,000). Both Utah and Vermont had the highest AAMR for European Americans (2.6/1,000,000). New York State and South Atlantic had the largest numbers of FSR-WASOG Sarcoidosis Clinics (6 and 13, respectively). States with better health rankings were significantly associated with lower AAMR in all population (R2 = 0.170, p = 0.003) but with higher AAMR in European Americans (R2 = 0.223, p < 0.001).
CONCLUSIONS: There are significant variations in sarcoidosis mortality within the US. Sarcoidosis mortality was strongly associated with state health disparities. The current study suggests sarcoidosis mortality could be an indicator to reflect the state-level health care disparities in the US.

Entities:  

Keywords:  USA; health disparity; mortality; sarcoidosis

Year:  2021        PMID: 34072248     DOI: 10.3390/jcm10112366

Source DB:  PubMed          Journal:  J Clin Med        ISSN: 2077-0383            Impact factor:   4.241


  29 in total

1.  A case control etiologic study of sarcoidosis: environmental and occupational risk factors.

Authors:  Lee S Newman; Cecile S Rose; Eddy A Bresnitz; Milton D Rossman; Juliana Barnard; Margaret Frederick; Michael L Terrin; Steven E Weinberger; David R Moller; Geoffrey McLennan; Gary Hunninghake; Louis DePalo; Robert P Baughman; Michael C Iannuzzi; Marc A Judson; Genell L Knatterud; Bruce W Thompson; Alvin S Teirstein; Henry Yeager; Carol J Johns; David L Rabin; Benjamin A Rybicki; Reuben Cherniack
Journal:  Am J Respir Crit Care Med       Date:  2004-09-03       Impact factor: 21.405

2.  World Trade Center "sarcoid-like" granulomatous pulmonary disease in New York City Fire Department rescue workers.

Authors:  Gabriel Izbicki; Robert Chavko; Gisela I Banauch; Michael D Weiden; Kenneth I Berger; Thomas K Aldrich; Charles Hall; Kerry J Kelly; David J Prezant
Journal:  Chest       Date:  2007-03-30       Impact factor: 9.410

Review 3.  Sarcoidosis.

Authors:  L S Newman; C S Rose; L A Maier
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

4.  Assessing the worldwide epidemiology of sarcoidosis: challenges and future directions.

Authors:  Yvette C Cozier
Journal:  Eur Respir J       Date:  2016-12       Impact factor: 16.671

5.  Sarcoidosis diagnosed after September 11, 2001, among adults exposed to the World Trade Center disaster.

Authors:  Hannah T Jordan; Steven D Stellman; David Prezant; Alvin Teirstein; Sukhminder S Osahan; James E Cone
Journal:  J Occup Environ Med       Date:  2011-09       Impact factor: 2.162

Review 6.  Multinational evidence-based World Association of Sarcoidosis and Other Granulomatous Disorders recommendations for the use of methotrexate in sarcoidosis: integrating systematic literature research and expert opinion of sarcoidologists worldwide.

Authors:  Johanna P Cremers; Marjolein Drent; Aalt Bast; Hidenobu Shigemitsu; Robert P Baughman; Dominique Valeyre; Nadera J Sweiss; Tim L Jansen
Journal:  Curr Opin Pulm Med       Date:  2013-09       Impact factor: 3.155

7.  Zirconium compound-induced pulmonary fibrosis.

Authors:  T Bartter; R S Irwin; J L Abraham; A Dascal; G Nash; J S Himmelstein; P J Jederlinic
Journal:  Arch Intern Med       Date:  1991-06

8.  Pharmacotherapy for pulmonary sarcoidosis: a Delphi consensus study.

Authors:  Amanda C Schutt; Wendy M Bullington; Marc A Judson
Journal:  Respir Med       Date:  2010-01-20       Impact factor: 3.415

9.  Sarcoidosis in America. Analysis Based on Health Care Use.

Authors:  Robert P Baughman; Shelli Field; Ulrich Costabel; Ronald G Crystal; Daniel A Culver; Marjolein Drent; Marc A Judson; Gerhard Wolff
Journal:  Ann Am Thorac Soc       Date:  2016-08

10.  High-Cost Sarcoidosis Patients in the United States: Patient Characteristics and Patterns of Health Care Resource Utilization.

Authors:  J Bradford Rice; Alan White; Andrea Lopez; Winnie W Nelson
Journal:  J Manag Care Spec Pharm       Date:  2017-10-17
View more
  1 in total

1.  Association of COVID-19 Case-Fatality Rate With State Health Disparity in the United States.

Authors:  Yu-Che Lee; Ko-Yun Chang; Mehdi Mirsaeidi
Journal:  Front Med (Lausanne)       Date:  2022-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.